Allergy

Autoimmune Diseases

Biosimilars

COVID-19

Cannabidiol (CBD)

Cardiology

Compounding

Continuous Glucose Monitoring

Dermatology

Diabetes

Digestive Health

Endocrinology

Eye Health

Generics

Headache and Migraine

Immunization

Infectious Disease

Influenza

Medical Devices

Mental and Behavioral Health

Neurology

Oncology

Pain Management

Pediatrics

Public Health

Rare Diseases

Respiratory

Rheumatology

Shingles

Substance Use Disorder

Technology and Data

Veterinary Pharmacy 

Women's Health

News

FDA Updates

Law and Advocacy

Technology Trends

Viewpoints

All News

Media

Around the Practice

In-Depth Insights

K-Casts

Script-Ed

Expert Interviews

Podcasts

Conferences

Conference Coverage

Conference Listing

Resources

Disease Awareness 

CME/CE

Partners

Publications

Drug Topics Journal

Total Pharmacy Journal

Events

Virtual Events

Total Pharmacy Solutions Summit

Business

Business Strategies

Patient Services

Pharmacy Inventory

Law and Regulations

All Business News

Practice Type

Independent Pharmacy

Chain Pharmacy

Specialty Pharmacy

Health System Pharmacy

Pharmacy Technicians

Subscribe

Articles

Check out important updates from the FDA for the week of April 15.

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

While prioritizing either cost or margin may be necessary at a site of care, big picture items, such as societal responsibility and long-term health care affordability, should guide financial analyses, said Scott Soefje, PharmD.

Balancing Cost and Margin for Sustainable Cancer Care

Representatives from the US Government Accountability Office (GAO) interviewed regulators from 5 states on pharmacy benefit manager laws.

GAO Releases Report on States’ Regulation of PBMs

Listening carefully to determine what’s beneath the surface of a patient’s concerns can make a world of difference in providing quality care.

Enhancing Patient-Pharmacist Relationships Through Conversation

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Drug Topics

Facebook

Twitter

LinkedIn

Spotlight

How to strengthen your team’s role as a trusted clinical advisor

IDWeek

Important Steps You Need To Take Before Choosing A Pharmacy Software Vendor: Not All Review Sites Are Created Equal

Improving Care For Every Patient

Protecting Public Health Through Quality in Vaccine Inventory Storage

NCPA

Optimizing Treatment Strategies for Diabetes

Proper Injection Technique Ensures Positive Outcomes Among Patients With Diabetes

Special Report: Pharmacy Finances

The Evolving Landscape of Influenza Immunizations

The Power of Community: Pharmacists Share Their Experiences With Service Expansion

Rethink Medication Adherence With Sustainable Multidose Packaging

1rem

Authors

Kendall Szulimowski is a 2021 PharmD candidate at the University of Connecticut School of Pharmacy in Storrs.

Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma. 

Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

Kendall Szulimowski, 2021 PharmD candidate

Articles